April 18 (Reuters) - Nykode Therapeutics ASA NYKD.OL :
* NYKODE THERAPEUTICS ANNOUNCES POSITIVE FINAL RESULTS FROM
ITS
PHASE 2 TRIAL OF VB10.16 IN COMBINATION WITH PD-L1 INHIBITOR
ATEZOLIZUMAB IN ADVANCED CERVICAL CANCER
* VB10.16 WAS SAFE AND WELL TOLERATED IN COMBINATION WITH
ATEZOLIZUMAB
* RESULTS SHOWED MEDIAN OVERALL SURVIVAL GREATER THAN 25
MONTHS
(NOT REACHED) AND 6.3 MONTHS MEDIAN PROGRESSION FREE SURVIVAL IN
PD-L1+ PATIENTS
Source text for Eikon: ID:nObiryk6sa
Further company coverage: NYKD.OL
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))